Trigger point injections for chronic non-malignant musculoskeletal pain: A systematic review

Pain Medicine

Volumn 10, Issue 1, 2009, Pages 54-69

  Scott, N Ann ^a   Guo, Bing ^a   Barton, Pamela M ^b,c   Gerwin, Robert D ^d,e  

^a INSTITUTE OF HEALTH ECONOMICS   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c CALGARY HEALTH REGION   (Canada)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Pain and Rehabilitation Medicine   (United States)

Author keywords

Chronic Pain; Myofascial Pain Syndrome; Myofascial Trigger Point; Systematic Review; Trigger Point Injection

Indexed keywords

BOTULINUM TOXIN A; BUPIVACAINE; HYALURONIC ACID; LIDOCAINE; PLACEBO; PRILOCAINE; TROPISETRON;

ARTHRALGIA; BACKACHE; CHRONIC PAIN; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; GANGLION BLOCK; HEADACHE; HUMAN; INTERNAL VALIDITY; MEDICAL LITERATURE; MUSCULOSKELETAL PAIN; NECK PAIN; OSTEOARTHRITIS; PATIENT SAFETY; PEER REVIEW; PHYSIOTHERAPY; REVIEW; SAMPLE SIZE; SHOULDER PAIN; STRETCHING EXERCISE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRIGGER POINT; ULTRASOUND THERAPY; WHIPLASH INJURY;

ANESTHETICS, LOCAL; CHRONIC DISEASE; HUMANS; MUSCLE STRETCHING EXERCISES; MYOFASCIAL PAIN SYNDROMES; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; REVIEW LITERATURE AS TOPIC; SHOULDER;

EID: 59649110656     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2008.00526.x     Document Type: Review

References (73)

1. Gitlin MC. Chronic non-cancer pain: An overview of assessment and contemporary management. J La State Med Soc 1999; 151: 93-8.
2. Hubbard DR, Jr. Chronic and recurrent muscle pain: Pathophysiology and treatment, and review of pharmacologic studies. J Musculoskelet Pain 1996; 4: 123-43.
3. Lang AM. Botulinum toxin therapy for myofascial pain disorders. Curr Pain Headache Rep 2002; 6: 355-60.
4. Simons DG, Travell JG, Simons LS. Travell & Simons' Myofascial Pain and Dysfunction: The Trigger Point Manual, vol. 1, upper half of body. Baltimore: Williams & Wilkins; 1999.
5. Borg-Stein J, Simons DG. Myofascial pain. Arch Phys Med Rehabil 2002; 83: S40-7.
6. Cummings TM, White AR. Needling therapies in the management of myofascial trigger point pain: A systematic review. Arch Phys Med Rehabil 2001; 82: 986-92.
7. Gerwin RD. Classification, epidemiology, and natural history of myofascial pain syndrome. Curr Pain Headache Rep 2001; 5: 412-20.
8. Hong C-Z. Considerations and recommendations regarding myofascial trigger point injection. J Musculoskelet Pain 1994; 2: 29-59.
9. Janssens LA. Trigger point therapy. Probl Vet Med 1992; 4: 117-24.
10. Fricton JR. Management of masticatory myofascial pain. Semin Orthod 1995; 1: 229-43.
11. Han SC, Harrison P. Myofascial pain syndrome and trigger-point management. Reg Anesth 1997; 22: 89-101.
12. Criscuolo CM. Interventional approaches to the management of myofascial pain syndrome. Curr Pain Headache Rep 2001; 5: 407-11.
13. Fast A. Low back disorders: Conservative management. Arch Phys Med Rehabil 1988; 69: 880-91.
14. Baldry P. Myofascial Pain and Fibromyalgia Syndromes. Edinburgh: Churchill Livingstone; 2001: 111-5.
15. Fischer AA. Algometry in the daily practice of pain management. J Back Musculoskelet Rehabil 1997; 8: 151-63.
16. Fischer AA. Injection techniques in the management of local pain. J Back Musculoskelet Rehabil 1996; 7: 107-17.
17. Evans RW. Some observations on whiplash injuries. Neurol Clin 1992; 10: 975-97.
18. Shah JP, Phillips TM, JDanoff JV, Gerber LH. An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol 2005; 99: 1977-84.
19. Scott A, Guo B. Trigger point injections for non-malignant chronic pain. HTA #35. Edmonton: Alberta Heritage Foundation for Medical Research, 2005. Available at: http://www.ihe.ca/documents/hta/HTA35.FINAL.pdf (accessed May 5, 2008).
20. International Association for the Study of Pain (IASP). Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Pain 1986; Suppl 3: S1-225.
21. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: Synthesis of best evidence for clinical decisions. Ann Intern Med 1997; 126: 376-80.
22. van Tulder MW, Assendelft WJ, Koes BW, Bouter LM. Method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group for spinal disorders. Spine 1997; 22: 2323-30.
23. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52: 377-84.
24. Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbe KA. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 1992; 45: 255-65.
25. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999; 282: 1054-60.
26. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. J Clin Epidemiol 1991; 44: 1271-8.
27. van Tulder MW, Furlan A, Bombardier C, Bouter LM, and the Editorial Board of the Cochrane Collaboration Back Review Group. Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine 2003; 28: 1290-9.
28. Byrn C, Olsson I, Falkheden L, et al. Subcutaneous sterile water injections for chronic neck and shoulder pain following whiplash injuries. Lancet 1993; 341: 449-52.
29. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994; 59: 65-9.
30. Ferrante FM, Kaufman AG, Dunbar SA, Cain CF, Cherukuri S. Sphenopalatine ganglion block for the treatment of myofascial pain of the head, neck, and shoulders. Reg Anesth Pain Med 1998; 23: 30-6.
31. Schnider P, Moraru E, Vigl M, etal. Physical therapy and adjunctive botulinum toxin type A in the treatment of cervical headache: A double-blind, randomised, placebo-controlled study. J Headache Pain 2002; 3: 93-9.
32. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998; 23: 1662-6.
33. Yentür EA, Okcu G, Yegul I. The role of trigger point therapy in knee osteoarthritis. Pain Clinic 2003; 15: 385-90.
34. Ferrante FM, Bearn L, Rothrock R, King L. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology 2005; 103: 377-83.
35. Müller W, Stratz T. The use of the 5-HT3 receptor antagonist tropisetron in trigger point therapy: A pilot study. J Musculoskelet Pain 2005; 13: 43-8.
36. Wheeler AH, Goolkasian P, Gretz SS. Botulinum toxin A for the treatment of chronic neck pain. Pain 2001; 94: 255-60.
37. Kamanli A, Kaya A, Ardicoglu O, etal. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 2005; 25: 604-11.
38. Kiralp MZ, Ari H, Karabekir I, Dursun H. Comparison of low intensity laser therapy and trigger point injection in the management of myofascial pain syndrome. Pain Clinic 2006; 18: 63-6.
39. Esenyel M, Caglar N, Aldemir T. Treatment of myofascial pain. Am J Phys Med Rehabil 2000; 79: 48-52.
40. Graboski CL, Gray DS, Burnham RS. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomised double blind crossover study. Pain 2005; 118: 170-5.
41. Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: A pilot study. Headache 2000; 40: 231-6.
42. Freund BJ, Schwartz M. Treatment of whiplash associated with neck pain with botulinum toxin-A: A pilot study. J Rheumatol 2000; 27: 481-4.
43. McMillan AS, Nolan A, Kelly PJ. The efficacy of dry needling and procaine in the treatment of myofascial pain in the jaw muscles. J Orofac Pain 1997; 11: 307-14.
44. Krishnan SK, Benzon HT, Siddiqui T, Canlas B. Pain on intramuscular injection of bupivacaine, ropivacaine, with and without dexamethasone. Reg Anesth Pain Med 2000; 25: 615-9.
45. Elias M. Cervical epidural abscess following trigger point injection. J Pain Symptom Manage 1994; 9: 71-2.
46. Nelson LS, Hoffman RS. Intrathecal injection: Unusual complication of trigger-point injection therapy. Ann Emerg Med 1998; 32: 506-8.
47. Parris WCV, Dettbarn WD. Muscle atrophy following bupivacaine trigger point injection. Anesthesiol Rev 1989; 16: 50-4.
48. Shafer N. Pneumothorax following "trigger point"injection. JAMA 1970; 213: 1193.
49. Spevak C. Asystole during trigger point injections in a patient with panic disorder. Reg Anesth 1997; 22: 583.
50. Alvarez DJ, Rockwell PG. Trigger points: Diagnosis and management. Am Fam Physician 2002; 65: 653-60.
51. Gerwin RD, Shannon S, Hong C-Z, Hubbard D, Gevirtz R. Interrater reliability in myofascial trigger point examination. Pain 1997; 69: 65-73.
52. Imamura M, Fischer AA, Imamura ST, etal. Treatment of myofascial pain components in plantar fasciitis speeds up recovery: Documentation by algometry. J Musculoskelet Pain 1998; 6: 91-110.
53. Sciotti VM, Mittak VL, DiMarco L, et al. Clinical precision of myofascial trigger point location in the trapezius muscle. Pain 2001; 93: 259-66.
54. Gerwin R, Shannon S. Interexaminer reliability and myofascial trigger points. Arch Phys Med Rehabil 2000; 81: 1257-8.
55. Hsieh C-Y, Hong C-Z, Adams AH, etal. Interexaminer reliability of the palpation of trigger points in the trunk and lower limb muscles. Arch Phys Med Rehabil 2000; 81: 258-64.
56. Ruane JJ. Identifying and injecting myofascial trigger points. Phys Sportsmed 20H1; 29: 12. Available at: http://www.physsportsmed.com/ issues/2001/12_01/clin_tech.htm (accessed May 5, 2008).
57. Myopain seminars. 2006. Available at: http://www.painpoints.com/seminars/ index.html (accessed May 5, 2008).
58. Sanders SH, Harden RN, Benson SE, Vicente PJ. Clinical practice guidelines for chronic non-malignant pain syndrome patients II: An evidence-based approach. J Back Musculoskelet Rehabil 1999; 13: 47-58.
59. College of Physicians and Surgeons of Ontario. Evidence-based recommendations for medical management of chronic non-malignant pain: Reference guide for clinicians. College of Physicians and Surgeons of Ontario, 2000. pp. 1-32. Available at: http://www.cpso.on.ca/ Publications/pain.PDF (accessed May 5, 2008).
60. North American Spine Society. North American Spine Society Phase III Clinical Guidelines for Multidisciplinary Spine Care Specialists. Ontario, Canada: College of Physicians and Surgeons of Ontario; 2000.
61. Physician Advisory Committee for the Oklahoma Workers' Compensation Court Administrator. Chronic Pain Treatment Guidelines. Oklahoma City, OK: Oklahoma Workers' Compensation Court; 1999: 1-10.
62. Airaksinen O, Brox JI, Cedraschi C, etal. Chapter 4. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J 2006; 15: S192-300.
63. Bourne IH. Treatment of chronic back pain. Comparing corticosteroid-lignocaine injections with lignocaine alone. Practitioner 1984; 228: 333-8.
64. Hameroff SR, Crago BR, Blitt CD, Womble J, Kanel J. Comparison of bupivacaine, etidocaine, and saline for trigger-point therapy. Anesth Analg 1981; 60: 752-5.
65. Garvey TA, Marks MR, Wiesel SW. A prospective, randomized, double-blind evaluation of trigger-point injection therapy for low-back pain. Spine 1989; 14: 962-4.
66. Hong C-Z. Lidocaine injection versus dry needling to myofascial trigger point. The importance of the local twitch response. Am J Phys Med Rehabil 1994b; 73: 256-63.
67. Pocock SJ. Clinical Trials: A Practical Approach. Chichester: Wiley; 1983.
68. Borg-Stein J, Stein J. Trigger points and tender points: One and the same? Does injection treatment help? Rheum Dis Clin North Am 1996; 22: 305-22.
69. Hawk C, Long CR. Use of a pilot to refine the design of a study to develop a manual placebo treatment. J Neuromusc Sys 2000; 8: 39-48.
70. Hawk C, Long CR, Reiter R, etal. Issues in planning a placebo-controlled trial of manual methods: Results of a pilot study. J Altern Complement Med 2002; 8: 21-32.
71. Lewith GT, Machin D. On the evaluation of the clinical effects of acupuncture. Pain 1983; 16: 111-27.
72. Moher D, Schulz KF, Altman D. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised controlled trials. JAMA 2001; 285: 1987-91.
73. MacPherson H, White A, Cummings M, etal. for the STRICTA Group. Standards for reporting interventions in controlled trials of acupuncture: The STRICTA recommendations. Acupunct Med 2002; 20: 22-5.